医学
回顾性队列研究
内科学
腹水
队列研究
胃肠病学
外科
队列
糖尿病
基线(sea)
临床试验
并发症
前瞻性队列研究
不利影响
作者
Daniel Riado Mínguez,Francisco Javier Parra Villanueva,Alejandra Cristina Rodríguez Heinsen,Flor María Fernández-Gordón Sánchez,Sandra Agudo,Cristina Cuadrado Tiemblo,Alicia Bejerano Domínguez,Carlos Castaño Milla
标识
DOI:10.17235/reed.2026.12277/2026
摘要
INTRODUCTION: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) may benefit fluid retention in cirrhosis, but evidence in decompensated patients remains limited. We evaluated the association between SGLT2i and documented ascites during follow-up in patients with cirrhosis and type 2 diabetes mellitus (T2DM) after a first episode of ascites. METHODS: A two-center retrospective cohort study of patients with cirrhosis and T2DM hospitalized for a first episode of ascites between 2017 and 2025 in Spain. Patients were classified according to SGLT2i use before admission. The primary endpoint was the presence of documented ascites at scheduled follow-up assessments after discharge. Secondary outcomes included relevant clinical and biochemical outcomes. RESULTS: Among 103 patients, 27 (26.2%) received SGLT2i and 76 (73.8%) did not. Median follow-up was 52 weeks [26-104]. SGLT2i users had a lower proportion of documented ascites (13/26 vs 53/66; 50% vs 80.3%; p=0.004). This association persisted after adjustment for potential confounders (aOR 0.23, 95% CI 0.08-0.66; p=0.006), with consistent results in a 6-month sensitivity analysis. No significant differences were observed in hospitalizations for ascites, for overall liver decompensation, LVPs, RA, hepatic encephalopathy, acute kidney injury or survival. Serum creatinine and sodium did not show differences between groups. 5/27 (18.5%) patients discontinued treatment. CONCLUSIONS: SGLT2i use was associated with a lower proportion of documented ascites after a first episode. Prospective studies are needed to establish their efficacy and safety in decompensated cirrhosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI